Compare STIM & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | BDSX |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5M | 101.7M |
| IPO Year | 2018 | 2020 |
| Metric | STIM | BDSX |
|---|---|---|
| Price | $1.34 | $15.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 2.4M | 118.5K |
| Earning Date | 05-01-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $52,776,000.00 | ★ $88,499,000.00 |
| Revenue This Year | $101.67 | $22.01 |
| Revenue Next Year | $10.87 | $26.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $1.20 | $0.25 |
| 52 Week High | $5.91 | $14.17 |
| Indicator | STIM | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 41.37 | 74.96 |
| Support Level | $1.26 | $6.33 |
| Resistance Level | $2.13 | N/A |
| Average True Range (ATR) | 0.17 | 1.55 |
| MACD | -0.02 | 0.25 |
| Stochastic Oscillator | 12.93 | 73.52 |
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.